ARPO Aerpio Pharmaceuticals, Inc. Stock Quote

ARPO [NASD]

Index	-	P/E	-	EPS (ttm)	-0.10	Insider Own	16.18%	Shs Outstand	42.14M	Perf Week	11.02%
Market Cap	62.78M	Forward P/E	-	EPS next Y	-0.55	Insider Trans	-0.28%	Shs Float	39.49M	Perf Month	31.00%
Income	-4.00M	PEG	-	EPS next Q	-0.14	Inst Own	41.50%	Short Float	3.50%	Perf Quarter	-2.24%
Sales	15.00M	P/S	4.19	EPS this Y	-87.10%	Inst Trans	-	Short Ratio	0.58	Perf Half Y	-9.66%
Book/sh	1.12	P/B	1.17	EPS next Y	-292.90%	ROA	-9.40%	Target Price	1.75	Perf Year	109.03%
Cash/sh	0.99	P/C	1.33	EPS next 5Y	-	ROE	-10.10%	52W Range	0.42 - 2.31	Perf YTD	33.67%
Dividend	-	P/FCF	-	EPS past 5Y	-	ROI	-	52W High	-43.29%	Beta	1.93
Dividend %	-	Quick Ratio	19.70	Sales past 5Y	-	Gross Margin	-	52W Low	211.90%	ATR	0.11
Employees	12	Current Ratio	19.70	Sales Q/Q	-	Oper. Margin	-	RSI (14)	54.96	Volatility	6.06% 6.93%
Optionable	No	Debt/Eq	0.00	EPS Q/Q	-2.70%	Profit Margin	-27.00%	Rel Volume	0.55	Prev Close	1.34
Shortable	Yes	LT Debt/Eq	0.00	Earnings	-	Payout	-	Avg Volume	2.37M	Price	1.31
Recom	2.00	SMA20	18.07%	SMA50	-6.32%	SMA200	5.48%	Volume	1,307,213	Change	-2.24%

Dec-09-20

Initiated

BTIG Research

Buy

Jul-23-18

Initiated

Needham

Buy

$10

Jan-14-21 10:46AM	Marinus (MRNS) Gets Positive FDA Response for Ganaxolone Study Zacks
Jan-12-21 10:27AM	Horizon (HZNP) Provides Preliminary 2020 Financial Results Zacks
10:04AM	Ultragenyx (RARE) Presents Preliminary 2020 Revenues & Guidance Zacks
Jan-06-21 09:48AM	Aerpio Pharmaceuticals (ARPO) Sees Hammer Chart Pattern: Time to Buy? Zacks
09:24AM	Aerpio (ARPO) Seeks Strategic Options for Pipeline Programs Zacks
Jan-05-21 04:01PM	Aerpio Announces Strategic Review after Topline Results from Razuprotafib Glaucoma Phase 2 Trial GlobeNewswire
Jan-04-21 09:34AM	Ultragenyx (RARE) Surges on Product Approvals, Pipeline Progress Zacks +7.14%
Dec-31-20 08:49AM	Arcturus (ARCT) to Develop ARCT-032 for Cystic Fibrosis Zacks
Dec-30-20 11:25AM	Novo Nordisk (NVO) Files for Ozempic's Label Expansion in EU Zacks
Dec-28-20 10:00AM	Apellis' (APLS) Pipeline Candidate Pegcetacoplan Promising Zacks
Dec-24-20 09:14AM	Bristol Myers' (BMY) CNS Phase III Cancer Study on Opdivo Fails Zacks
Dec-23-20 10:06AM	Roche's (RHHBY) Phesgo Gets EU Nod to Treat Breast Cancer Zacks
Dec-22-20 10:22AM	ChemoCentryx (CCXI) Reports Positive Top-Line Rare Disease Data Zacks
Dec-21-20 10:13AM	Novo Nordisk (NVO) Files for Semaglutide Label Expansion in EU Zacks
Dec-18-20 11:15AM	Ultragenyx (RARE), Mereo Ink Deal for Bone Disease Candidate Zacks
Dec-16-20 01:31PM	Novartis' (NVS) Entresto Gets FDA Panel Nod for Expanded Use Zacks -7.89%
Dec-15-20 10:54AM	Sangamo Therapeutics (SGMO) Catches Eye: Stock Jumps 6.5% Zacks -5.00%
09:57AM	Roche (RHHBY) Gets FDA Nod for Shorter Infusion Time of Ocrevus Zacks
Dec-14-20 01:04PM	Seagen (SGEN) Gets Positive CHMP Opinion for Breast Cancer Drug Zacks -46.67%
12:59PM	Bristol Myers (BMY) Gets Positive CHMP Opinion for Inrebic Zacks
12:00PM	What Makes Aerpio Pharmaceuticals, Inc. (ARPO) a Strong Momentum Stock: Buy Now? Zacks
Dec-11-20 05:00PM	Aerpio Announces Statistically Significant Topline Results from Razuprotafib Glaucoma Phase 2 Trial GlobeNewswire
08:34AM	Alkermes (ALKS) Outlines Value Enhancement Plan, Shares Up Zacks
Dec-10-20 09:40AM	Ultragenyx (RARE) Gets Orphan Drug Tag for Wilson Disease Drug Zacks +7.77%
Dec-09-20 08:45AM	Sesen Bio (SESN) Surges: Stock Moves 7.8% Higher Zacks
08:33AM	Checkmate (CMPI), Bristol Myers Ink Deal for Cancer Combo Zacks
Dec-08-20 08:56AM	Chimerx's (CMRX) NDA for Brincidofovir Accepted by FDA Zacks +16.28%
Dec-07-20 09:27AM	FDA Approves Label Expansion of Novo Nordisk's (NVO) Saxenda Zacks
09:27AM	FDA Approves Label Expannsion of Novo Nordisk's (NVO) Saxenda Zacks
09:13AM	Bayer (BAYRY) Inks Deal With Atara for CAR-T Cell Therapies Zacks
Dec-04-20 08:45AM	Alnylam (ALNY) Ends Enrollment in Advanced Hyperoxaluria Study Zacks
08:32AM	Five Star (FVE) in Focus: Stock Moves 5.8% Higher Zacks
08:29AM	Deere & Co, Chico's FAS, Aerpio Pharmaceuticals, TRACON Pharmaceuticals and Repligen Corp highlighted as Zacks Bull and Bear of the Day Zacks
Dec-03-20 09:06PM	Is Aerpio Pharmaceuticals (ARPO) A Good Stock To Buy Now? Insider Monkey
10:23AM	BioNTech (BNTX) Surges: Stock Moves 6.2% Higher Zacks
Nov-15-20 07:21AM	Introducing Aerpio Pharmaceuticals (NASDAQ:ARPO), The Stock That Zoomed 214% In The Last Year Simply Wall St.
Nov-10-20 08:00AM	Aerpio Reports Third Quarter 2020 Financial Results and Provides Business Update GlobeNewswire -7.97%
Nov-05-20 04:01PM	Aerpio Pharmaceuticals to Report Third Quarter 2020 Financial Results on November 10 GlobeNewswire
04:01PM	Aerpio Hosting Key Opinion Leader Call on New Therapeutic Agents for COVID-19 GlobeNewswire
Oct-26-20 05:06PM	11 Stocks Moving In Monday's After-Hours Session Benzinga
04:01PM	Aerpio Announces First Patient Dosed with Razuprotafib in the Phase 2 Trial for the Prevention and Treatment of ARDS in Patients with Moderate-to-Severe COVID-19 GlobeNewswire
Sep-17-20 07:00AM	Aravive Appoints Michael W. Rogers to Board of Directors GlobeNewswire +14.81%
Sep-15-20 08:30AM	Aerpio Announces Enrollment Completed in the 28-Day Phase 2 Razuprotafib Glaucoma Trial GlobeNewswire +5.08%
Sep-01-20 04:30PM	Aerpio and Quantum Leap Announce First Patients Dosed with Razuprotafib in the I-SPY COVID Trial to Treat ARDS in Critically-ill COVID-19 Patients PR Newswire -5.49%
04:30PM	Aerpio and Quantum Leap Announce First Patients Dosed with Razuprotafib in the I-SPY COVID Trial to Treat ARDS in Critically-ill COVID-19 Patients GlobeNewswire
Aug-17-20 11:06AM	Here's Why We're Not Too Worried About Aerpio Pharmaceuticals' (NASDAQ:ARPO) Cash Burn Situation Simply Wall St.
Aug-12-20 08:00AM	Aerpio Reports Second Quarter 2020 Financial Results and Provides Business Update GlobeNewswire
Aug-10-20 08:00AM	Aerpio Pharmaceuticals to Report Second Quarter 2020 Financial Results on August 12 GlobeNewswire
Aug-05-20 07:35AM	The Daily Biotech Pulse: Novavax Vaccine Data, Aerpio Gets $5.1M Funding For COVID Trial, Rigel Gains Big On Earnings Benzinga +14.39%
Aug-04-20 04:15PM	Aerpio Pharmaceuticals, Inc. Announces a Second Clinical Trial with Funding from MTEC to Evaluate Razuprotafib for the Prevention and Treatment of ARDS in Patients with Moderate to Severe COVID-19 GlobeNewswire
Jun-29-20 05:50PM	Aerpio Pharmaceuticals, Inc. (ARPO) Outpaces Stock Market Gains: What You Should Know Zacks
11:30AM	Is Aerpio Pharmaceuticals (ARPO) Outperforming Other Medical Stocks This Year? Zacks
Jun-24-20 08:00AM	Aerpio Announces Initiation of 28-Day Phase 2 Razuprotafib Glaucoma Trial GlobeNewswire
Jun-22-20 07:24AM	Aerpio Pharmaceuticals' Shares March Higher, Can It Continue? Zacks
Jun-19-20 05:45PM	Aerpio Pharmaceuticals, Inc. (ARPO) Gains As Market Dips: What You Should Know Zacks
12:37PM	Top Ranked Momentum Stocks to Buy for June 19th Zacks
Jun-15-20 10:07AM	New Strong Buy Stocks For June 15th Zacks
08:32AM	Leap Therapeutics (LPTX) Soars: Stock Adds 8.3% in Session Zacks
Jun-12-20 11:30AM	Is Aerpio Pharmaceuticals (ARPO) Stock Outpacing Its Medical Peers This Year? Zacks +7.69%
Jun-08-20 04:44PM	Aerpio Announces Change to Virtual Format for its 2020 Annual Meeting of Stockholders due to COVID-19 GlobeNewswire +8.70%
09:00AM	Aerpio Hosting Key Opinion Leader Call on a Novel Mechanism for the Treatment of Glaucoma GlobeNewswire
Jun-05-20 08:46AM	New Strong Buy Stocks For June 5th Zacks
May-29-20 09:59AM	Company News for May 29, 2020 Zacks
07:22AM	The Daily Biotech Pulse: ASCO Presentations Begin, Altimmune Pops On Insider Buying, Immutep Gets R&D Grant Benzinga
May-27-20 04:30PM	Aerpio Pharmaceuticals, Inc. and Quantum Leap Healthcare Collaborative Announce the Selection of Razuprotafib for Evaluation in the I-SPY COVID Trial for the Treatment of Acute Respiratory Distress Syndrome in COVID-19 Patients GlobeNewswire
11:30AM	Is Aerpio Pharmaceuticals (ARPO) Outperforming Other Medical Stocks This Year? Zacks
May-26-20 07:49AM	New Strong Buy Stocks For May 26th Zacks
May-21-20 12:00PM	Aerpio Pharmaceuticals, Inc. (ARPO) Upgraded to Strong Buy: Here's Why Zacks
08:01AM	New Strong Buy Stocks For May 21st Zacks
May-13-20 07:40AM	The Daily Biotech Pulse: Gilead Signs Manufacturing Deal For Remdesivir, Bristol-Myers Gets Refuse-To-File Letter Benzinga +25.14%
May-12-20 04:30PM	Aerpio Announces Amended Licensing Deal with Gossamer Bio on its Inflammatory Bowel Disease (IBD) Product Candidate GB004 (formerly AKB-4924) GlobeNewswire
May-11-20 11:30AM	Is Aerpio Pharmaceuticals (ARPO) Stock Outpacing Its Medical Peers This Year? Zacks
May-07-20 08:00AM	Aerpio Reports First Quarter 2020 Financial Results and Provides Business Update GlobeNewswire
May-06-20 05:45PM	Aerpio Pharmaceuticals, Inc. (ARPO) Gains As Market Dips: What You Should Know Zacks
Apr-24-20 07:24AM	New Strong Buy Stocks for April 24th Zacks +13.83%
Apr-22-20 05:50PM	Aerpio Pharmaceuticals, Inc. (ARPO) Gains But Lags Market: What You Should Know Zacks
11:30AM	Has Aerpio Pharmaceuticals (ARPO) Outpaced Other Medical Stocks This Year? Zacks
Apr-20-20 10:46AM	New Strong Buy Stocks For April 20th Zacks +17.79%
Apr-16-20 08:39AM	Immunovant (IMVT) Catches Eye: Stock Jumps 5% Zacks +14.32%
Apr-09-20 06:35AM	Does Aerpio Pharmaceuticals, Inc. (NASDAQ:ARPO) Have A High Beta? Simply Wall St.
Apr-08-20 12:00PM	Aerpio Pharmaceuticals, Inc. (ARPO) Moves to Strong Buy: Rationale Behind the Upgrade Zacks
Mar-16-20 08:00AM	Aerpio Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Business Update GlobeNewswire -7.14%
Mar-12-20 05:00PM	Aerpio Pharmaceuticals to Report Year Ended December 31, 2019 Financial Results on Monday, March 16, 2020 GlobeNewswire
Feb-09-20 09:49AM	Those Who Purchased Aerpio Pharmaceuticals (NASDAQ:ARPO) Shares A Year Ago Have A 80% Loss To Show For It Simply Wall St.
Feb-07-20 06:20PM	Aerpio Pharmaceuticals Presents Data from Fifth Patient Cohort Showing Potential of Topical Ocular Formulation of AKB-9778 Product Candidate When Combined with Prostaglandin in Subjects with Primary Open Angle Glaucoma or Ocular Hypertension Business Wire
Jan-08-20 08:43AM	Topical Ocular Formulation of Aerpio Pharmaceuticals AKB-9778 Product Candidate Produced IOP Lowering with Minimal Hyperemia When Combined with Prostaglandin in Subjects with Primary Open Angle Glaucoma or Ocular Hypertension in Phase 1b Trial Business Wire -6.94%
Dec-22-19 05:08PM	Hedge Funds Are Buying Aerpio Pharmaceuticals, Inc. (ARPO) Insider Monkey
Nov-11-19 06:59AM	Here's Why We're A Bit Worried About Aerpio Pharmaceuticals's (NASDAQ:ARPO) Cash Burn Situation Simply Wall St.
Nov-07-19 07:00AM	Aerpio Reports Third Quarter 2019 Financial Results and Provides Business Update Business Wire
Oct-21-19 11:09AM	Cincinnati firms stock jumps amid C-suite shakeup, possibility of sale or merger American City Business Journals +15.08%
05:00AM	Aerpio Pharmaceuticals Announces Review of Strategic Alternatives Business Wire
Oct-10-19 02:30PM	Aerpio Pharmaceuticals Announces Interim Results from its Phase 1b Clinical Trial of Topical Ocular Formulation of AKB-9778 for Primary Open Angle Glaucoma Business Wire -8.03%
Oct-09-19 09:00AM	All You Need to Know About Aerpio Pharmaceuticals, Inc. (ARPO) Rating Upgrade to Buy Zacks
Aug-14-19 04:59PM	Cincinnati stocks hammered as Dow suffers fourth-biggest drop American City Business Journals
Aug-08-19 07:00AM	Aerpio Reports Second Quarter 2019 Financial Results and Provides Business Update Business Wire
Jul-05-19 01:09PM	This Cincinnati stock gained 457% in the first half of 2019: SLIDESHOW American City Business Journals
Jun-10-19 07:00AM	Aerpio Initiates Phase 1b Clinical Trial of Topical Ocular Formulation of AKB-9778 for Primary Open Angle Glaucoma Business Wire
May-14-19 12:36PM	Wall Street Sees 3 Falling Knives Rebounding Within 52 Weeks GuruFocus.com
May-09-19 07:00AM	Aerpio Reports First Quarter 2019 Financial Results and Provides Business Update Business Wire
May-02-19 07:00AM	Aerpio Pharmaceuticals Presents Data Showing Potential of AKB-9778, a VE-PTP Inhibitor/Tie2 Activator, to Lower Intra-ocular Pressure in Human Subjects Business Wire

Aerpio Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing and commercializing compounds for the treatment of ocular diseases and diabetic complications. The company's lead product candidate is razuprotafib, a small molecule activator of the Tie2 pathway, which completed the Phase IIb clinical trial for the treatment of diabetic retinopathy. It also develops ARP-1536, a humanized monoclonal antibody that is in preclinical development stage for the treatment of diabetic vascular complications; GB004, a selective stabilizer of hypoxia-inducible factor-1 alpha, which is in a Phase 1b clinical trial for the treatment of inflammatory bowel disease; and bispecific antibody for the treatment for wet age-related macular degeneration and DME through intravitreal injection. Aerpio Pharmaceuticals, Inc. has a collaboration with Quantum Leap Healthcare Collaborative for the evaluation of razuprotafib in the treatment of acute respiratory distress syndrome in adult patients with moderate to severe COVID-19. The company is headquartered in Cincinnati, Ohio.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
ORBIMED ADVISORS LLC	10% Owner	Dec 08	Sale	1.96	21,400	41,944	0	Dec 10 05:04 PM

open in yahoo | open in reuters | open in google

Upgrade your FINVIZ experience